A Clinical Trial of Pembrolizumab in Patients with Hepatitis B Virus-related Hepatocellular Carcinoma, with Parallel Study on Baseline and Serial Change in the Immune Environment
Latest Information Update: 16 Dec 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 12 Dec 2024 Planned End Date changed from 30 Dec 2025 to 30 Dec 2026.
- 12 Dec 2024 Planned primary completion date changed from 30 Dec 2024 to 30 Dec 2025.
- 21 Nov 2023 Planned End Date changed from 30 Dec 2024 to 30 Dec 2025.